Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$389.12M |
$0.26
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$384.72M |
$19.70
-8.20%
|
|
BLDE
Blade Air Mobility, Inc.
Blade's Medical segment provides healthcare logistics services including organ transport and related operations.
|
$383.21M |
$4.73
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$381.13M |
$10.11
-3.90%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$380.87M |
$56.59
-8.33%
|
|
GNE
Genie Energy Ltd.
Health Insurance: Captive insurance subsidiary offering tailored health insurance products to retail customers.
|
$380.60M |
$14.24
+0.46%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$379.42M |
$1.76
+18.12%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$376.00M |
$7.12
-5.44%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
QTRX
Quanterix Corporation
Quanterix directly manufactures and sells ultra-sensitive diagnostic instruments (Simoa platforms) used for biomarker detection in blood and other samples.
|
$374.52M |
$8.25
+26.73%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$367.63M |
$4.25
-0.59%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$365.47M |
$5.50
-4.09%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$361.71M |
$10.37
+1.57%
|
|
RXST
RxSight, Inc.
RxSight's core offering is the Light Adjustable Lens system and related ophthalmic devices used in premium cataract surgery, which fits Ophthalmology Devices.
|
$361.70M |
$8.73
-8.78%
|
|
AUNA
Auna S.A.
AUNA operates hospitals and provides inpatient and outpatient care, i.e., hospital services.
|
$360.98M |
$4.88
-2.10%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$359.52M |
$2.31
-1.07%
|
|
SOPH
SOPHiA GENETICS S.A.
Liquid Biopsy: MSK-ACCESS application and liquid biopsy analytics integrated into the platform.
|
$357.50M |
$5.29
+6.55%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$354.79M |
$4.01
-1.59%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$351.59M |
$7.80
-4.06%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$350.27M |
$7.47
+2.40%
|
|
ACIU
AC Immune S.A.
Alzheimer's Disease Therapeutics – the company focuses on active immunotherapies and diagnostic assets for Alzheimer's disease.
|
$343.15M |
$3.46
+0.58%
|
|
MTLS
Materialise N.V.
Materialise's Mimics platform centers on medical imaging analysis and planning workflows.
|
$340.82M |
$5.75
-2.21%
|
|
AHG
Akso Health Group
Online hospital services and broader hospital/clinical service platform.
|
$330.74M |
$1.56
+17.29%
|
Showing page 19 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
